A61K 39/275
Poxviridae
Official title: Poxviridae, e.g. avipoxvirus
A61K39/275 (Poxviridae) appears on 279 US grants and 392 published applications in this corpus.
Search patents in A61K- Granted patents
- 279
- Published applications
- 392
- Assignees
- 209
- Inventors
- 561
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 4 | 0 |
| 2002 | 0 | 3 |
| 2003 | 2 | 11 |
| 2004 | 6 | 8 |
| 2005 | 4 | 11 |
| 2006 | 8 | 12 |
| 2007 | 5 | 16 |
| 2008 | 6 | 13 |
| 2009 | 8 | 19 |
| 2010 | 10 | 27 |
| 2011 | 23 | 28 |
| 2012 | 18 | 17 |
| 2013 | 15 | 17 |
| 2014 | 16 | 16 |
| 2015 | 11 | 13 |
| 2016 | 14 | 11 |
| 2017 | 12 | 22 |
| 2018 | 17 | 18 |
| 2019 | 16 | 15 |
| 2020 | 13 | 20 |
| 2021 | 14 | 23 |
| 2022 | 11 | 15 |
| 2023 | 6 | 21 |
| 2024 | 11 | 15 |
| 2025 | 13 | 7 |
| 2026 | 5 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- Conditions improving poxvirus stability9 Jun 2026US 12,648,992 B2Bavarian Nordic A/S
- Smallpox vaccine for cancer treatment26 May 2026US 12,636,361 B2Calidi Biotherapeutics (Nevada), Inc.
- Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines27 Jan 2026US 12,533,410 B2Arcturus Therapeutics, Inc.
- Synthetic chimeric vaccinia virus20 Jan 2026US 12,529,036 B2Tonix Pharma Limited
- Methods of Isolating Poxviruses from Avian Cell Cultures27 Aug 2026US 2026/0248906 A1Bavarian Nordic A/S
- Multi-antigen chimeric vaccine against poxvirus and use thereof20 Aug 2026US 2026/0240989 A1Institute of Microbiology, Chinese Academy of Sciences
- Recombinant chimeric antigen for poxvirus, subunit vaccine comprising same and use thereof6 Aug 2026US 2026/0226110 A1Beihang University
- Pharmaceutical compositions, vaccines and their uses in the prevention or treatment of a persistent infection or of cancer23 Jul 2026US 2026/0207735 A1Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- Compositions and Methods for Enhancement of mRNA Vaccine Performance and Vaccination against Mpox18 Jun 2026US 2026/0166138 A1Yale University
Most cited
By later US patents
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Microorganisms for therapy104US 7,588,767 B2Genelux Corporation · 2009
- Modified vaccinia ankara virus variant99US 6,761,893 B2Bavarian Nordic A/S · 2004
- Microorganisms for therapy98US 7,754,221 B2Genelux Corporation · 2010
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001